🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Amrutanjan Health Care Limited AMRUTANJAN NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.amrutanjan.com
Company Profile ↓
₹541.20
-26.02% 1Y
Mkt Cap₹1,564.64 Cr
P/E30.78
P/B4.22
Div. Yield1.04%
52W High₹763.43
52W Low₹493.65
Book Value₹128.06
EPS (TTM)₹17.58

Company Overview

Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms brand name; and fruit and rehydration juice drinks under the Fruitnik brand name. The company also offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints, as well as provides sanitary napkins for women. In addition, it operates a pain management center. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.4%.

Consistent Profit Growth

Net profit has compounded at 13.3% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 30.8, below the sector median of 39.7.

Recent Developments

  • Mar 2026 Revenue of ₹502.55 Cr (+11.2% YoY); net profit ₹57.92 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +11.2%, earnings +13.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.9%, profit CAGR 13.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.94%
1 Year:11.23%

Compounded Profit Growth

5 Years:13.29%
1 Year:13.93%

Stock Price Performance

1 Year:-26.02%
6 Months:-13.32%
3 Months:+0.65%
1 Month:-2.42%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 18% of range
₹493.65 ₹763.43
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)47.81 · Neutral
Price Performance
1M-2.42%
3M+0.65%
6M-13.32%
1Y-26.02%
Valuation vs Sector

P/E of 30.78 is below the sector median of 39.70 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 20.4%.
  • Profit CAGR of 13.3% over 5 years.

CONS

  • Trading 29.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
30.78
Industry PE
39.70
Forward P/E est.
27.02
PEG Ratio
-
Book Value
₹128.06
Price to Book
4.22
P/S
3.11
EV/EBITDA
20.26
Dividend Yield
1.04%

Growth (CAGR)

Revenue 5Y
9.94%
Profit 5Y
13.29%
Revenue (YoY)
11.23%
Earnings (YoY)
13.93%

Profitability & Returns

ROCE
20.40%
ROE
15.64%
ROA
11.38%
Profit Margin
11.52%
Op Margin
12.29%
Gross Margin
51.38%
EPS (Latest Qtr)
₹5.60
EPS (TTM)
₹17.58

Balance Sheet & Liquidity

Debt/Equity
0.48
Quick Ratio
2.02
Current Ratio
2.31
Debt
₹1.78 Cr
Total Assets
₹508.89 Cr
Current Assets
₹291.65 Cr
Working Capital
₹165.46 Cr

Ownership

Promoter Holding
49.15%
Chg in Prom Hold
-4.74%
FII / Inst Holding
12.11%
Chg in FII Hold
-2.72%

Financial Snapshot

Enterprise Value
₹1,564.64 Cr
Total Revenue (TTM)
₹502.55 Cr
EBITDA
₹84.40 Cr
Free Cash Flow
₹-19.04 Cr
Operating Cash Flow
₹35.97 Cr
Shares Outstanding
₹2.89 Cr
Gross Margin
51.38%
Payout Ratio
22.97%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AMRUTANJAN Amrutanjan Health Care Limited NSEPHARMA 541.20 30.78 ₹1,564.64 Cr 1.04% 20.40% 15.64% 9.94% 13.29%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -135.41 Cr94.05 Cr117.70 Cr141.04 Cr149.77 Cr
Cost of Revenue -68.99 Cr49.39 Cr57.66 Cr63.79 Cr73.52 Cr
Gross Profit -66.42 Cr44.66 Cr60.05 Cr77.25 Cr76.25 Cr
Operating Expenses -50.34 Cr37.74 Cr45.08 Cr53.70 Cr59.91 Cr
Operating Income -16.08 Cr6.92 Cr14.97 Cr23.54 Cr16.33 Cr
EBITDA -22.52 Cr12.87 Cr20.82 Cr28.04 Cr22.67 Cr
Interest Expense -4.33 L5.15 L4.97 L4.79 L4.59 L
Pretax Income -20.86 Cr11.29 Cr19.21 Cr26.36 Cr21.02 Cr
Tax Provision -5.68 Cr2.98 Cr5.25 Cr6.91 Cr4.82 Cr
Net Income -15.18 Cr8.31 Cr13.96 Cr19.45 Cr16.19 Cr
Diluted EPS -5.252.874.836.735.60

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 67.00 Cr69.00 Cr71.00 Cr87.00 Cr86.00 Cr101.00 Cr136.00 Cr131.00 Cr134.00 Cr158.00 Cr177.00 Cr-378.23 Cr420.12 Cr451.82 Cr502.55 Cr
Cost of Revenue ------------181.98 Cr211.83 Cr223.21 Cr244.36 Cr
Gross Profit ------------196.25 Cr208.29 Cr228.61 Cr258.19 Cr
Operating Expenses 53.00 Cr53.00 Cr60.00 Cr182.00 Cr76.00 Cr88.00 Cr118.00 Cr113.00 Cr112.00 Cr134.00 Cr145.00 Cr-154.18 Cr160.28 Cr176.93 Cr196.43 Cr
Operating Income 10.00 Cr14.00 Cr9.00 Cr-97.00 Cr9.00 Cr11.00 Cr15.00 Cr13.00 Cr18.00 Cr21.00 Cr28.00 Cr-42.06 Cr48.02 Cr51.67 Cr61.76 Cr
EBITDA 13.00 Cr16.00 Cr11.00 Cr-95.00 Cr10.00 Cr13.00 Cr18.00 Cr17.00 Cr22.00 Cr24.00 Cr31.00 Cr-58.93 Cr68.16 Cr75.88 Cr84.40 Cr
Interest Expense 1.00 Cr1.00 Cr1.00 Cr001.00 Cr3.00 Cr2.00 Cr2.00 Cr1.00 Cr0-7.71 L15.67 L21.92 L19.50 L
Pretax Income 11.00 Cr11.00 Cr9.00 Cr123.00 Cr19.00 Cr15.00 Cr16.00 Cr15.00 Cr19.00 Cr24.00 Cr33.00 Cr-53.65 Cr61.95 Cr69.13 Cr77.89 Cr
Tax Provision 4.95 Cr5.06 Cr3.78 Cr30.75 Cr7.22 Cr5.10 Cr6.24 Cr5.25 Cr6.84 Cr9.12 Cr12.21 Cr-13.81 Cr16.97 Cr18.30 Cr19.97 Cr
Net Income 6.00 Cr6.00 Cr5.00 Cr92.00 Cr11.00 Cr10.00 Cr10.00 Cr10.00 Cr12.00 Cr15.00 Cr21.00 Cr-39.83 Cr44.97 Cr50.83 Cr57.92 Cr
Diluted EPS ---29.80--3.323.474.265.107.0522.9813.6315.5017.58-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 37.00 Cr41.00 Cr48.00 Cr111.00 Cr118.00 Cr157.00 Cr124.00 Cr124.00 Cr120.00 Cr124.00 Cr140.00 Cr-362.09 Cr366.87 Cr421.39 Cr508.89 Cr
Current Assets ------------259.95 Cr295.68 Cr290.67 Cr291.65 Cr
Cash & Equivalents ------------67.56 Cr25.76 Cr80.38 Cr11.27 Cr
Inventory ------------28.83 Cr28.90 Cr27.26 Cr37.35 Cr
Receivables ------------33.02 Cr47.89 Cr55.82 Cr60.64 Cr
Total Liabilities ------------71.32 Cr78.38 Cr94.77 Cr138.66 Cr
Current Liabilities ------------63.01 Cr69.92 Cr84.58 Cr126.18 Cr
Long Term Debt ----------------
Total Debt 6.00 Cr8.00 Cr8.00 Cr1.00 Cr1.00 Cr30.00 Cr22.00 Cr15.00 Cr8.00 Cr2.00 Cr2.00 Cr-90.91 L1.73 Cr2.08 Cr1.78 Cr
Total Equity 18.00 Cr23.00 Cr26.00 Cr93.00 Cr97.00 Cr101.00 Cr77.00 Cr82.00 Cr89.00 Cr95.00 Cr109.00 Cr-290.77 Cr288.49 Cr326.61 Cr370.23 Cr
Shares Outstanding ------------2.92 Cr2.89 Cr2.89 Cr2.89 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 10.00 Cr11.00 Cr5.00 Cr6.00 Cr11.00 Cr6.00 Cr4.00 Cr9.00 Cr17.00 Cr18.00 Cr21.00 Cr-20.18 Cr27.91 Cr50.90 Cr35.97 Cr
Investing Cash Flow 3.00 Cr-4.00 Cr-8.00 Cr89.00 Cr-47.00 Cr-29.00 Cr14.00 Cr13.00 Cr16.00 Cr-5.00 Cr4.00 Cr--2.48 Cr19.16 Cr-30.97 Cr-21.23 Cr
Financing Cash Flow -12.00 Cr-1.00 Cr-2.00 Cr-30.00 Cr-8.00 Cr20.00 Cr-27.00 Cr-14.00 Cr-14.00 Cr-12.00 Cr-13.00 Cr--14.99 Cr-48.27 Cr-13.49 Cr-13.62 Cr
Capital Expenditure 2.00 Cr-4.00 Cr-8.00 Cr83.00 Cr-5.00 Cr-11.00 Cr-4.00 Cr-1.00 Cr0-5.00 Cr-2.00 Cr--8.93 Cr-6.72 Cr-35.55 Cr-55.00 Cr
Free Cash Flow 12.00 Cr7.00 Cr-3.00 Cr89.00 Cr6.00 Cr-5.00 Cr-08.00 Cr17.00 Cr13.00 Cr19.00 Cr-11.25 Cr21.19 Cr15.35 Cr-19.04 Cr
Net Change in Cash 1.00 Cr6.00 Cr-5.00 Cr65.00 Cr-43.00 Cr-4.00 Cr-9.00 Cr8.00 Cr20.00 Cr1.00 Cr12.00 Cr-2.72 Cr-1.19 Cr6.44 Cr1.12 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ------------51.9%49.6%50.6%51.4%
Operating Margin % 14.9%20.3%12.7%-111.5%10.5%10.9%11.0%9.9%13.4%13.3%15.8%-11.1%11.4%11.4%12.3%
Net Margin % 9.0%8.7%7.0%105.7%12.8%9.9%7.4%7.6%9.0%9.5%11.9%-10.5%10.7%11.3%11.5%
ROE % 33.3%26.1%19.2%98.9%11.3%9.9%13.0%12.2%13.5%15.8%19.3%-13.7%15.6%15.6%15.6%
ROCE % ------------14.1%16.2%15.3%16.1%

Shareholding Pattern

Insiders
49.15%
Institutions
12.11%
Public Float
23.82%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMRUTANJAN

Google News Mon, 09 Feb 2026

Individual investors who hold 31% of Amrutanjan Health Care Limited (NSE:AMRUTANJAN) gained 10%, insiders profited as well - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPVHcwa0haQS03UkpySWJhZnh0a1RmMlZQZ0xneFdWbjJDR0NRS0xwTVc2RXFBQm1ZYVU5eVQ2U3VLSlFieUJWNmFFRVJYb2hfYTlLTkJPZnpXSmhRMTNBQ1YtQWNFTlhrWUVldnR6d2VMeWtJQ3lBamFqanE5ZHRLYXVlSUdsbzZSUVdUOG…

Google News Wed, 13 May 2026

Amrutanjan FY26 PAT Rises 14%; Board Recommends Dividend - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPc3M3b01pc1d4UjdITmtXbF9kV21vYmE1Z2d6dGVoZ1Y3UHBPcmpiMVdHMjU2SW9YN3Y2UVVOdzRQUWNLcFNwSkM5TTFnQ3NBcHpaZzZPejc2QWlXSG11SGhJcFhVQU5oVF9OSUZJcDhvZ04wX2ZJZ3Jaa1BYNlh2TmlCYWUxUHp4RHFfTl…

Google News Mon, 19 Jan 2026

Amrutanjan Health Care Ltd. Share Price Today - Amrutanjan Health Care Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxORkRhQVBMaUp6ZEZNOWQxS18wTExmcVZuTzh1dmZkZVhyX3hEdS1teHlHRzdYRkFBbnY4RnhkV0Z4SzEwMzRDa0tYazFFU3BuWFZjM2c1ZFV5MkZuUG1Db2ROd25WTHNHLVphdFNrQVlDZjZhODMyaUZwQVZpQmVHa1U2V201V21lOVU0WA…

Google News Sat, 22 Nov 2025

There May Be Underlying Issues With The Quality Of Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxQWGJmSExrazNHUjBxVzdVYkw5SlFDQ1JzT1JTWWlYbi1USkJHQjRKdlQxdkgyVHc4Q0F6RWFBSm9SdU1xX2pKZFotQzFLNUpLWG5zSDVCYnFaSWNROWhwVG0yamkzNTNreFRBanVlTHUtd05OYjNwTE9ENEM5bHdJN2V5Tjl0VGJMcmUxRz…

Google News Mon, 17 Nov 2025

Want dividends? Keep an eye on these 10 stocks today; check full list - Business Standard

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPcExQUWlFLXBDdnVoZGxrWFVtZVVidk84VGdoc2ZpMmk5RF84Q21POTZwOS0zNXpmUmU3SXpQRlpjSTdoWno2VGZhOU0xTU1XSFFTSzhyOXZVaFhXaWZPd3hKaURWelFaeVktSEpTU3RZaTZvUkJxTm95ZTlmb1hSWVRSYVFTZkhxV2NiT1…

Google News Fri, 17 Apr 2026

Amrutanjan Health Care Launches New Product Range in Personal Care, Wound Care and Pain Management - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQYnV3dDJwNzRZNVQ0X25pSG9HcmlaM3BNUnY4VC1pUFVDSkxqVUU4dmNtZXJRR0pPNHU5N3lsMUp1WW5qMTdLQ0R2Nk9uUG9ockx0YktJaWRGR3llcHVGVGtIQzczaV9oeHY4VVFiMml2VDlPcWlwUmJydzZCN2d2N2lodXE0OXNzTklBcG…

AMRUTANJAN — Frequently Asked Questions

What is the current share price of Amrutanjan Health Care Limited (AMRUTANJAN)?

As of 2026-07-16 05:21 IST, Amrutanjan Health Care Limited (AMRUTANJAN) trades at ₹541.20 on NSE. Its 52-week range is ₹493.65 to ₹763.43.

What is the market capitalisation of AMRUTANJAN?

Amrutanjan Health Care Limited (AMRUTANJAN) has a market capitalisation of ₹1,564.64 Cr on NSE.

What is the P/E ratio of AMRUTANJAN?

AMRUTANJAN trades at a trailing price-to-earnings (P/E) ratio of 30.78. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 4.22.

Does AMRUTANJAN pay a dividend?

Amrutanjan Health Care Limited (AMRUTANJAN) currently offers a dividend yield of 1.04%.

What is the return on equity (ROE) of AMRUTANJAN?

AMRUTANJAN has a return on equity (ROE) of 15.64%. Its return on capital employed (ROCE) is 20.40%.

Is AMRUTANJAN a good stock to buy?

This page provides a data-driven analysis of Amrutanjan Health Care Limited (AMRUTANJAN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space